Currently available IBs illuminate only a small proportion of the tumour pathologies so there is a pressing need to develop measures of proliferation, apoptosis and necrosis into biomarkers which can reliably support both positive and negative decisions.
Through a portfolio of highly innovative approaches to devise, evaluate and introduce IBs of invasion and metastasis, the QuIC-ConCePT vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase I trials of investigational therapies that can be readily deployed in multiple cancer centres in a robust, consistent, ethical, and cost-effective way acceptable to patients. The results of the QuIC-ConCePT work should have utility in cancer research and in patient management in a very wide range of other important settings.
The managing entity European Organisation for Research and Treatment of Cancer (EORTC) is already a world leader in the qualification of IBs and the consortium includes some of the world's most productive and innovative physicians and scientists in cancer imaging. The QuIC-ConCePT project will work in close collaboration with the newly approved FP7 project EuroBioImaging “Research infrastructure for imaging technologies in biological and biomedical sciences” coordinated by EIBIR and EMBL. EORTC will ensure the link between the two projects fostering crossfertilization and preventing duplication.
The QuIC-ConCept consortium partners consist of 14 academic organisations combined with 1 SME working with 7 EFPIA companies over 5 years.